FDA Expands CorPath Robotic System Labeling To Radial PCIs
This article was originally published in The Gray Sheet
Executive Summary
The company says as radial percutaneous coronary interventions continue to grow, FDA's 510(k) clearance gives more radiologists and interventional cardiologists access to a system that reduces their exposure to radiation.
You may also be interested in...
Corindus Vascular Robotics Names Chief Medical Officer
Interventional cardiologist J. Aaron Grantham will serve as Corindus Vascular Robotics' chief medical officer.
Remote PCI: Corindus Explores Performing Cardiac Caths From Miles Away With Robotics
Corindus Vascular Robotics, Sanford Health and Helmsley Charitable Trust are partnering on a study of remote robotic-assisted PCI for patients in rural areas.
Robot-Assisted PCI: Corindus Plans Gradual Launch For Newly Cleared System
The company announced 510(k) clearance of its CorPath 200 System July 25, calling it the “first and only” robot-assisted tool that allows percutaneous coronary interventions to be performed from an interventional cockpit.